ClinicalTrials.gg

Chronic Pain clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,228 studies for Chronic Pain across more than 10 countries. 729 are recruiting or about to start. 1,902 of them are mainly about Chronic Pain (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 7,912 studies for Chronic Pain. How that becomes 3,227 here

This page counts the studies the registry files under Chronic Pain, and those it files under no condition that list Chronic Painthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 7,912Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −258List Chronic Pain as a condition, but the registry did not file them under itMost often written as “Knee Pain Chronic” (95), “Hip Pain Chronic” (26), and “Chronic Pain Syndrome” (23). The registry filed them under other conditions only, most often Osteoarthritis, Knee (63) and Pain, Postoperative (46).
  3. −4,427Match it another way460 name it in the title, 39 in a keyword, and 3,928 by a synonym or other text the search reads.
  4. 3,227The count on this page103 of them list Chronic Pain in their own words; the registry filed them under no condition.

Status

Completed
1,791
Recruiting
487
Status unknown
304
Not yet recruiting
196
Active, not recruiting
160
Terminated
142

Phase

Phase 2
189
Phase 3
159
Phase 4
125
Phase 1
112
Early Phase 1
27

Where

United States
1,283
Turkey
203
Canada
202
Spain
174
France
135
United Kingdom
116

Who develops what

Add Chronic Pain to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 5 with this as their studies’ main aim; 0 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Sichuan Kelun Pharmaceutical and Eli Lilly here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
LidocaineRecent, limited
Evidence
  • NCT05707208 · Sustained Therapeutics Inc. · Phase 2 · comparator · “1% Lidocaine HCL” · registered Jan 2023
Keenova Therapeutics plc17% of its industry studiesUS: off-patent, 62 generics marketed11 study
TramadolEarlier only
Evidence
  • NCT05125978 · EMS · Phase 2 · comparator · “Tramadol hydrochloride” · registered Nov 2021
  • NCT02722603 · pharmaceutical research management srl · Phase 3 · comparator · “tramadol” · registered Mar 2016
Johnson & Johnson37% of its industry studiesUS: off-patent, 12 generics marketed00 studies
OxycodoneEarlier only
Evidence
  • NCT01427283 · Knoa Pharma · Phase 3 · comparator · “Oxycodone HCl controlled-release” · registered Aug 2011
  • NCT01427270 · Knoa Pharma · Phase 3 · comparator · “Oxycodone HCl controlled-release” · registered Aug 2011
  • NCT00449176 · Johnson & Johnson · Phase 3 · comparator · “oxycodone CR” · registered Mar 2007
  • NCT00421928 · Johnson & Johnson · Phase 3 · comparator · “oxycodone” · registered Jan 2007
Mundipharma28% of its industry studiesUS: off-patent, 39 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Mar 2027 est.cebranopadol · Adneuris Therapeutics, Inc. · Phase 2 main aimNCT07874620 A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain — primary endpoint: Clinical Opiate Withdrawal Scale (COWS) Total Score Maximum Effect (Emax) from 0 to 48 hours · 45 enrolled
  • Apr 2027 est.LY4065967 · Eli Lilly and Company · Phase 2 main aimNCT07641504 A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain — primary endpoint: Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) · 150 enrolled
  • Apr 2027 est.LY4065967 · Eli Lilly and Company · Phase 2 named, not the main aimNCT07641517 A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain — primary endpoint: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) · 150 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Chronic Pain studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Opioids 7 open · Local anesthetics 5 open · Psychedelics 5 open · Corticosteroids 4 open · Serotonin receptor agonists 4 open

Coming up

292studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 487 Chronic Pain studies recruiting now, 240 (49%) set no upper age limit and 173 (36%) stop at 75 or younger. 43 (9%) take children under 18. 31 (6%) are for women only and 3 (1%) for men only; 64 (13%) take healthy volunteers.

Recruiting studies that take each age, of 487
AgeWomenMen
1020 (4%)21 (4%)
18388 (80%)369 (76%)
30415 (85%)388 (80%)
40423 (87%)395 (81%)
50426 (87%)401 (82%)
65433 (89%)409 (84%)
75344 (71%)333 (68%)
85274 (56%)267 (55%)

Across all 3,228 studies, recruiting or not: 38% stop at 75 or younger and 26% at 65; 8% take children; 8% are for women only and 2% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Chronic Pain studies take

Of 60 phase 1 interventional studies under Chronic Pain, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 112 mo6–56 · 60 studies6 mo3–12 · 27 studies—
Phase 237 mo21–52 · 60 studies—42 mo25–52 · 47 studies
Phase 337 mo22–56 · 49 studies——
Phase 424 mo14–38 · 52 studies—23 mo14–40 · 50 studies
Interventional, no phase20 mo9–38 · 1,379 studies21 mo10–30 · 83 studies20 mo9–39 · 1,296 studies
Observational24 mo12–56 · 362 studies—24 mo11–56 · 336 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting20

Show 15 more

Newly registered21

Show 16 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,228. Browse all 3,228 → or search them.